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Antiplatelet Effects of Clopidogrel and Aspirin
Day 1 Day 30 Day 180 p-
value
Clopidogrel
effect
VerifyNow PRU 169 (92, 240) 183 (122, 252) 194 (125, 245) 0.047
- PRU >208 36.4% 40.9% 42.2% 0.40
RPA ADP 5mM 11 (4, 22) 17 (8, 29) 15 (6, 31) 0.003
RPA ADP 20mM 24 (10, 43) 36 (22, 49) 32 (17, 49) 0.007
Aspirin effect VerifyNow ARU 393 (384, 408) 394 (384, 409) 395 (380, 411) 0.55
RPA AA 500 mg/
L
4 (2, 7) 6 (3, 8) 5 (4, 8) 0.18
Results shown as median (interquartile range); p-values by Friedman test.
Analysis Population
and Events
Rates in Propensity
Matched Groups*
Hazard Ratio (95%
Conﬁdence Interval)*
Overall Analysis
Population
Bivalirudin Heparin±GPI
30-day GUSTO
bleeding
3.0% 4.1% 0.72 (0.57-0.90)
30-day MACE 7.6% 8.2% 0.91 (0.78-1.06)
Bivalirudin Group Prasugrel Clopidogrel
30-day GUSTO
bleeding
2.7% 2.5% 1.07 (0.64-1.77)
30-day MACE 7.5% 6.7% 1.09 (0.80-1.48)
Heparin±GPI Group Prasugrel Clopidogrel
30-day GUSTO
bleeding
4.0% 4.3% 0.90 (0.63-1.30)
30-day MACE 5.4% 6.8% 0.85 (0.63-1.15)
*Unadjusted event rates and hazard ratios compare each outcome between treatment groups
after 1:1 propensity matching within the described analysis population.
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Background: Diabetic patients with acute coronary syndrome (ACS) undergoing
percutaneous coronary intervention (PCI) frequently exhibit high platelet reactivity
(HPR) while on clopidogrel. We aimed to test the hypothesis that in diabetic patients
with ACS undergoing PCI exhibiting HPR after standard treatment with clopidogrel, a
loading dose of 60 mg of prasugrel is superior to the standard treatment with clopi-
dogrel for the achievement of optimal P2Y12 inhibition within the ﬁrst 24-36 hours
post-PCI.
Methods: The VERDI was a prospective, randomized, single-center, single-blind,
parallel design study (NCT01684813). Consecutive diabetic patients with ACS un-
dergoing PCI and loaded with clopidogrel were considered for platelet reactivity (PR)
assessment immediately before PCI with the VerifyNow assay (Accumetrics Inc, San
Diego, CA), measured in P2Y12 reaction units (PRU). Out of 63 screened patients, 50
(79.3%) patients were found with HPR (deﬁned as PRU 208) and were randomized
to receive a loading dose of 60 mg prasugrel vs the standard dose of clopidogrel.
Platelet function was assessed again 24h post-PCI.
Results: Greater platelet inhibition was achieved by prasugrel compared with clopi-
dogrel at 24h post-PCI [38 (9-72) vs 285 (240-337), respectively; median (inter-
quartile range); p < 0.001]. The primary end point of non-HPR rate (PRU < 208) at
24h post-PCI was higher in the prasugrel group, twenty-ﬁve patients (100%) in the
prasugrel group achieved optimal antiaggregation versus 4 patients (16%) in the
clopidogrel group; p < 0.001. No signiﬁcant acute bleeding was documented in either
group.
Conclusions: Among type 2 diabetic patients with ACS and HPR undergoing PCI
with stent, switching from clopidogrel to prasugrel was superior to standard treatment
with clopidogrel for the achievement of optimal antiaggregation within the ﬁrst 24h
post-PCI.
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Background: Previous studies had reported that high platelet reactivity (HPR) is
associated with recurrent ischemic events after PCI. However, 1st generation drug-
eluting stents (DES) were mainly used in those studies. We measured platelet reac-
tivity after clopidogrel loading, late lumen loss by quantitative coronary angiographic
analysis (QCA) and assessed mid-term clinical outcomes in patients who underwent
PCI with 2nd generation DES.
Methods: Platelet reactive units (PRU) was measured by VerifyNow P2Y12 assays in
396 patients underwent PCI with Everolimus- or Biolimus-eluting stents between
August 2010 and May 2013. All patients received 300mg clopidogrel loadingB146 JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstraimmediately after PCI, 368 patients were followed by a maintenance dose of clopi-
dogrel (75-50mg/d) and aspirin (100mg/d). Blood samples were obtained 12 to 24
hours after PCI (initial phase) and 2-4 weeks later (chronic phase). HPR on clopidgrel
was deﬁned as 240 or more in PRU. We assessed major adverse cardiovascular event
(MACE) including the composite of death, nonfatal MI, stent thrombosis, stroke, and
target lesion revascularization (TLR), and bleeding events, QCA was evaluated at
baseline and 1-year follow-up.
Results: The value of PRU and rate of HPR on the chronic phase were signiﬁcantly
lower than in the initial phase (24981 vs. 21483; p< 0.001, 58% vs. 42%; p<
0.001). In the chronic phase, HPR group had more female and older patients than non-
HPR group. There were no signiﬁcant differences in MACE and bleeding events
between two groups (HPR 7.7% vs. non-HPR 7.5%; p¼NS). According to QCA, late
lumen loss was signiﬁcantly larger in HPR group compared to non-HPR group
(0.290.40mm vs. 0.170.37mm; p¼0.01). Multiple logistic regression analysis
indicated that HPR was the only independent predictor for late lumen loss of 0.3mm
and over (p¼0.015).
Conclusions: There was no signiﬁcant impact of platelet reactivity on clopidogrel on
clinical outcomes after PCI with 2nd generation DES. However, adequate inhibition of
platelet reactivity reduced late lumen loss.
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Background: Clinical studies have demonstrated an association between high on-
treatment platelet reactivity and ischemic events after coronary stent placement,
suggesting that platelet function testing may be used to guide antiplatelet therapy.
However, periprocedural platelet activation may falsely increase the proportion of
patients with high on-treatment platelet reactivity. We therefore investigated the
temporal variability in response to clopidogrel and aspirin for up to 6 months after
elective coronary placement of drug-eluting stents.
Methods:We determined platelet reactivity in whole blood (VerifyNow P2Y12 and
Aspirin assays) and in platelet rich plasma (light transmission aggregometry - LTA)
obtained from 121 unselected patients on day 1 after PCI following loading with
aspirin (300 mg), clopidogrel (600mg), and administration of the ﬁrst mainte-
nance dose of clopidogrel 75mg, followed by measurements on day 30 and day
180 after PCI on chronic treatment (clopidogrel 75mg qd, ASA 100mg qd). Re-
sidual platelet aggregation (RPA) was determined by LTA using adenosine
diphosphate (ADP; 5 and 20mM) and arachidonic acid (AA; 500 mg/L). P2Y12
Reaction Units (PRU) and Aspirin Reaction Units (ARU) were assessed using
VerifyNow assays.
Results: As seen in the Table, platelet inhibition in response to aspirin was consistent
from day 1 to 180. The platelet response to clopidogrel decreased slightly over time.
However, deﬁning clopidogrel hyporesponsiveness as a PRU >208, the percentages
of hyporesponsive patients were 36.4%, 40.9% and 42.2% on day 1, 30 and 180
respectively (p¼0.40).Conclusions: Serial platelet function testing measured 1 day after aspirin and clopi-
dogrel loading and PCI reliably reﬂects the response to antiplatelet treatment for at
least 6 months.cts/Pharmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors
